LGND
Ligand Pharmaceuticals Inc - Class B
PEG ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: LGND
- PEG Ratio
As of Aug 21, 2026, LGND's PEG ratio of 0.08 reflects its valuation relative to its growth. This value reflects a P/E ratio of 28.43 measured against EPS growth of 347.4%.
LGND PEG ratio history
Ligand Pharmaceuticals Inc - Class B's nine years historical PEG ratio has a mean of 0.17. Compared to historical data, LGND's 0.08 PEG ratio represents a decrease of 53%. LGND reached its maximum PEG ratio of 1.5 during the Sep 2017 quarter over the past nine years. The Mar 2019 quarter had the bottom reading at 0, indicating the most optimal growth-adjusted valuation.
Ligand Pharmaceuticals Inc - Class B PEG ratio by year
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| 2025 | 0.01 | 29.36 | 3,027.3% |
| 2024 | N/A | N/A | -107.3% |
| 2023 | 0.09 | 23.65 | 252.5% |
| 2022 | N/A | N/A | -157.6% |
| 2021 | 0.02 | 44.9 | 2,011.1% |
| 2020 | N/A | N/A | -100.5% |
| 2019 | 0.01 | 3.15 | 389.4% |
| 2018 | 0.02 | 20.04 | 1,028.3% |
| 2017 | 0.27 | 228.22 | 850% |
| 2016 | N/A | N/A | -100.7% |
| 2015 | 0.01 | 9.34 | 1,867.8% |
| 2014 | 16.7 | 90.19 | 5.4% |
| 2013 | 0.05 | 93.93 | 1,966.7% |
| 2012 | N/A | N/A | -106.1% |
| 2011 | 0.13 | 24.22 | 192.5% |
Ligand Pharmaceuticals Inc - Class B PEG ratio by quarter (TTM)
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| Jun 2026 | 0.09 | 31.39 | 347.4% |
| Mar 2026 | 0.12 | 25.27 | 209.7% |
| Dec 2025 | 0.01 | 29.36 | 3,027.3% |
| Sep 2025 | N/A | 76.68 | -12.5% |
| Jun 2025 | N/A | N/A | -266.8% |
| Mar 2025 | N/A | N/A | -232.1% |
| Dec 2024 | N/A | N/A | -107.3% |
| Sep 2024 | 0.22 | 37.91 | 175% |
| Jun 2024 | 0.62 | 34.53 | 55.4% |
| Mar 2024 | 0.05 | 13.41 | 292.1% |
| Dec 2023 | 0.09 | 23.65 | 252.5% |
| Sep 2023 | 0.36 | 62.42 | 175.6% |
| Jun 2023 | 0.11 | 45.92 | 434% |
| Mar 2023 | N/A | 52.92 | -2.1% |
| Dec 2022 | N/A | N/A | -157.6% |
LGND average PEG ratio chart
LGND's PEG ratio today is lower than the 3, 5 and 10-year averages.
PEG comparison
With a PEG of 0.08, LGND stands below the Healthcare sector and the industry average. Looking at its Healthcare sector average of 0.61, Ligand Pharmaceuticals Inc - Class B's PEG is 87% lower.
LGND EPS growth
LGND Price vs fair value
LGND PEG vs peers
LGND has a PEG ratio below that of peer stocks LLY and AMGN.
Frequently asked questions
What is Ligand Pharmaceuticals Inc - Class B's PEG ratio?
LGND's Aug 21, 2026 PEG ratio comes in at 0.08.
What is the 3-year average PEG ratio for Ligand Pharmaceuticals Inc - Class B (LGND)?
LGND has a 3-year average PEG ratio of 0.2.
What is the 5-year average PEG ratio for Ligand Pharmaceuticals Inc - Class B (LGND)?
LGND has a 5-year average PEG ratio of 0.15.
What is the highest PEG ratio for LGND?
In the last nine years, LGND's peak PEG ratio of 1.5 was recorded in the Sep 2017 quarter.
How does the current PEG ratio for LGND compare to its historical average?
Currently, LGND's PEG ratio is 53% lower than its 9-year historical average.
Why is Ligand Pharmaceuticals Inc - Class B's PEG ratio so low?
The 0.08 PEG ratio for LGND reflects strong earnings growth outpacing the current valuation.
How is LGND's PEG ratio calculated (Ligand Pharmaceuticals Inc - Class B PEG ratio formula)?
The PEG ratio comes from taking PE and dividing by the rate at which earnings are growing (YoY TTM). As of Aug 21, 2026, Ligand Pharmaceuticals Inc - Class B has a P/E ratio of 28.43. Earnings grew at 347.4% over the TTM period ending Jun 2026. Applying the formula, this gives a price to earnings growth ratio of 0.08. PEG RATIO(0.08) = PE RATIO(28.43) / EPS GROWTH(347.4%)
All PEG ratio stats are based on quarterly TTM periods, unless otherwise specified.